Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo-l-prolinase in glutathione modulation in tumor cells

Biochemical Pharmacology

Volumn 56, Issue 6, 1998, Pages 743-749

  Chen, Xiang ^b   Batist, Gerald ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

5 oxo L prolinase; Glutamate; Glutathione; L 2 oxothiazolidine 4 carboxylate; Melphalan; Sensitization to chemotherapy

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; 5 OXOPROLINASE; GLUTATHIONE; MELPHALAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; SENSITIZATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG SYNERGISM; GLUTATHIONE; HUMANS; MELPHALAN; PYROGLUTAMATE HYDROLASE; PYRROLIDONECARBOXYLIC ACID; THIAZOLES; THIAZOLIDINES; TUMOR CELLS, CULTURED;

EID: 0032530204     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00223-8     Document Type: Article

References (37)

1. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:1994;4313-4320.
2. Meister A. Selective modification of glutathione metabolism. Science. 220:1983;472-477.
3. Biaglow J.E., Varnes M.E., Clark E.P., Epp E. The role of thiols in cellular response to radiation and drugs. Radiat Res. 95:1983;437-455.
4. Van der Werf P., Orlowski M., Meister A. Enzymatic conversion of 5-oxo-L-proline (L-pyrrolidone carboxylate) to L-glutamate coupled with cleavage of adenosine triphosphate to adenosine diphosphate, a reaction in the γ-glutamyl cycle. Proc Natl Acad Sci USA. 68:1971;2982-2985.
5. Van der Werf P., Stephani R.A., Orlowski M., Meister A. Inhibition of 5-oxoprolinase by 2-imidazolidone-4-carboxylic acid. Proc Natl Acad Sci USA. 70:1973;759-761.
6. Van der Werf P., Meister A. The metabolic formation and utilization of 5-oxo-L-proline (L-pyroglutamate, L-pyrrolindone carboxylate). Adv Enzymol Relat Areas Mol Biol. 43:1975;519-556.
7. Meister A. 5-Oxoprolinuria (pyroglutamic aciduria) and other disorders of the γ-glutamyl cycle. Stanbury J.B., Wyngaarden J.B., Fredrickson D.S., Goldstein J.L., Brown M.S. The Metabolic Basis of Inherited Diseases. 1983;348-359 McGraw-Hill, New York.
8. Henderson M.J., Larsson A., Carlsson B., Dear P.R.F. 5-Oxoprolinuria associated with 5-oxoprolinase deficiency Further evidence that this is a benign disorder . J Inher Metab Dis. 16:1993;1051-1052.
9. Williamson J.M., Boettcher B., Meister A. Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci USA. 79:1982;6246-6249.
10. Russo A., Mitchell J.B. Radiation response of Chinese hamster cells after elevation of intracellular glutathione levels. Int J Radiat Oncol Biol Phys. 10:1984;1243-1247.
11. Russo A., DeGraff W., Friedman N., Mitchell J.B. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res. 46:1986;2845-2848.
12. Tsan M.F., Phillips P.G. L-2-Oxothiazolidine-4-carboxylate protects cultured endothelial cells against hyperoxia-induced injury. Inflammation. 12:1988;113-121.
13. Jain A., Madsen D.C., Auld P.A., Frayer W.W., Schwartz M.K., Meister A., Martensson J. L-2-Oxothiazolidine-4-carboxylate, a cysteine precursor, stimulates growth and normalizes tissue glutathione concentrations in rats fed a sulfur amino acid-deficient diet. J Nutr. 125:1995;851-856.
14. Taylor C.G., Bauman P.F., Sikorski B., Bray T.M. Elevation of lung glutathione by oral supplementation of L-2-oxothiazolidine-4-carboxylate protects against oxygen toxicity in protein-energy malnourished rats. FASEB J. 6:1992;3101-3107.
15. Baruchel S., Wang T., Farah R., Alaoui-Jamali M.A., Batist G. In vivo selective modulation of tissue glutathione in a rat mammary carcinoma model. Biochem Pharmacol. 50:1995;1505-1508.
16. Wang T., Chen X., Schecter R.L., Baruchel S., Alaoui-Jamali M., Melnychuk D., Batist G. Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor response. J Pharmacol Exp Ther. 276:1996;1169-1173.
17. Chen X., Schecter R.L., Griffith O.W., Hayward M.A., Alpert L.C., Batist G. Characterization of 5-oxo-L-prolinase in normal and tumor tissues of humans and rats A potential new target for biochemical modulation of glutathione . Clin Cancer Res. 4:1998;131-138.
18. Meister A., Griffith O.W., Williamson J.M. 5-Oxo-L-prolinase from rat kidney. Methods Enzymol. 113:1985;445-451.
19. Griffith O.W. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologues, potent inhibitors of glutathione synthesis. J Biol Chem. 257:1982;13704-13712.
20. Plumb J.A., Milroy R., Kaye S.B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 42:1989;4435-4440.
21. Anderson M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 113:1985;548-551.
22. Batist G., Schecter R., Woo A., Greene D., Lehnert S. Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines. Biochem Pharmacol. 41:1991;631-635.
23. White R.D., Wilson D.M., Glosson J.A., Madsen D.C., Bruce R.W., Goldberg D.I. Toxicity evaluations of L-cysteine and Procystiene™, a cysteine prodrug, given once intravenously to neonatal rats. Toxicol Lett. 69:1993;15-24.
24. Puente J., Devoto M.A., Sapag-Hagar M. Modulation of γ-glutamyl cycle and glutathione levels in rat mammary gland explants. Int J Tissue React. 8:1986;105-110.
25. Weitberg A.B. The effect of L-2-oxothiazolidine on glutathione levels in cultured mammalian cells. Mutat Res. 191:1987;189-191.
26. Bank B.B., Hanganis D., Liebes L.F., Silber R. Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes. Cancer Res. 49:1989;554-559.
27. Kramer R.A., Greene K., Ahmad S., Vistica D.T. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res. 47:1987;1593-1597.
28. Ozols R.F., Louie K.G., Plowman J., Behrens B.C., Fine R.L., Dykes D., Hamilton T.C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol. 36:1987;147-152.
29. Mulcahy T.R., Bailey H.H., Gipp J.J. Transfection of complementary DNAs for the heavy and light subunits of human γ-glutamylcysteine synthetase results in an evaluation of intracellular glutathione and resistance to melphalan. Cancer Res. 55:1995;4771-4775.
30. Batist G., Torres-Garcia S., Demuys J.M., Greene D., Lehnert S., Rochon M., Panasci L. Enhanced DNA cross-link removal The apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line . Mol Pharmacol. 36:1989;224-230.
31. Williamson J.M., Meister A. Stimulation of hepatic glutathione formation by administration of L-2-oxothiazolidine-4-carboxylate, a 5-oxo-L-prolinase substrate. Proc Natl Acad Sci USA. 78:1981;936-939.
32. Matsuno T., Goto I. Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma. Cancer Res. 52:1992;1192-1194.
33. Matsuno T. Bioenergetics of tumor cells Glutamine metabolism in tumor cell mitochondria . Int J Biochem. 19:1987;303-307.
34. Kang Y.J. Buthionine sulfoximine spares intracellular glutamate A possible mechanism for cell growth stimulation . Cell Mol Biol Res. 39:1993;675-684.
35. Moslen M.T., Whitehead R.F., Ferguson A.E., Kanz M.F. Protection by L-2-oxothiazolidine-4-carboxylate, a cysteine prodrug, against 1,1-dichloroethylene hepatotoxicity in rats is associated with decreases in toxin metabolism and cytochrome P-450. J Pharmacol Exp Ther. 248:1989;157-163.
36. Caffrey P.B., Frenkel G.D. The development of drug resistance by tumor cells in vitro is accompanied by the development of sensitivity to selenite. Cancer Lett. 81:1994;59-65.
37. Hamilton T.C., Winker M.A., Louie K.G., Batist G., Behrens B.C., Tsuruo T., Grotzinger K.R., McKoy W.M., Young R.C., Ozols R.F. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol. 34:1985;2583-2586.